¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : Á¦Ç° À¯Çüº°, ¹é½Å À¯Çüº°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Microneedle Flu Vaccine Market, By Product Type, By Vaccine Type, By Application, By Country, and By Region - Industry Analysis, Market Application, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1606438
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 288 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 16¾ï 3,043¸¸ ´Þ·¯·Î, 2024-2032³â CAGR 6.30%·Î È®´ë

¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå - ½ÃÀå ¿ªÇÐ

¹é½Å µô¸®¹ö¸® °­È­ & ¹«¹Ù´Ã Åõ¿©¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ Àü¸Á

¸¶ÀÌÅ©·Î´Ïµé µ¶°¨ ¹é½Å Á¢Á¾Àº Çdz» Åõ¿©¸¦ ÅëÇØ ¸é¿ª ¹ÝÀÀÀ» °­È­ÇÕ´Ï´Ù. º¸´Ù È¿°úÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ ¹é½Å ±â¼ú¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Åõ¿©´Â ±âÁ¸ÀÇ ¹Ù´ÃÀ» »ç¿ëÇÏ´Â ¹é½Å°ú °ü·ÃµÈ µÎ·Á¿ò°ú ºÒ¾ÈÀ» ÁÙÀ̰í ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¶°¨ÀÌ °øÁß º¸°Ç¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¹é½Å äÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, COVID-19 ÆÒµ¥¹ÍÀº È®Àå °¡´ÉÇϰí Á¢±Ù °¡´ÉÇϸç È¿À²ÀûÀÎ ¹é½Å ¼Ö·ç¼ÇÀÇ Çʿ伺À» °­Á¶ÇÏ°í ¸¶ÀÌÅ©·Î´Ïµé ±â¼ú¿¡ ´ëÇÑ °ü½ÉÀ» ³ô¿´½À´Ï´Ù. º¸ÆíÀû ¿¹¹æÁ¢Á¾À» °­Á¶ÇÏ´Â Ä·ÆäÀÎÀº Çõ½ÅÀûÀÎ Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

ƯÈ÷ µ¶°¨¿¡ °É¸®±â ½¬¿î ³ë³âÃþÀº º¸´Ù ¾ÈÀüÇÏ°í Æí¾ÈÇÑ ¹é½Å Á¢Á¾ ¹æ¹ýÀ» ÇÊ¿ä·Î Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀçÅÃÄ¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö´Â °ÍÀº ÀÚ°¡ Åõ¿©°¡ °¡´ÉÇÑ ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡ÀÇ Æ¯¼º°úµµ ÀÏÄ¡ÇÕ´Ï´Ù. ³¯Ä«·Î¿î Æó±â¹°À» ¾ø¾Ö°í ȯ°æ¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Ư¼öÇÑ Æó±â ½Ã½ºÅÛÀÇ Çʿ伺À» ÁÙÀÔ´Ï´Ù. ÀÇ·á Á¾»çÀÚÀÇ ¹Ù´Ã¿¡ Âñ¸®´Â ºÎ»óÀÇ À§ÇèÀ» ÁÙÀÔ´Ï´Ù. ¶ÇÇÑ ¸¶ÀÌÅ©·Î´Ïµé ½Ã½ºÅÛÀº ¾à¹°Àü´Þ°ú °°Àº ƯÁ¤ ¿ëµµ¿¡ »ç¿ëµÇ¸ç, ±¤¹üÀ§ÇÑ »ó¾÷Àû Ȱ¿ëÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé µ¶°¨ ¹é½Å ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¸Å³â ¾à 6.30%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â Áß°ø ¸¶ÀÌÅ©·Î´Ïµé ¼¼ºÐÈ­°¡ ¹é½Å¿¡ ´ëÇÑ È¿´ÉÀ¸·Î ÀÎÇØ 22023³â °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¹é½Å À¯Çü¿¡ µû¶ó 4°¡ µ¶°¨ ¹é½Å ºÎ¹®Àº ¹ÙÀÌ·¯½º ±ÕÁÖ¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Àû¿ëÀ¸·Î ÀÎÇØ 2023³â ¹é½Å À¯Çü ºÎ¹®À» ÁÖµµÇß½À´Ï´Ù.

¿ëµµº°·Î´Â ¾à¹°Àü´Þ ºÐ¾ß°¡ 2023³â ÁÖ¿ä ¿ëµµ·Î ²ÅÇû½À´Ï´Ù.

Áö¿ªº°·Î º¸¸é 2023³â ºÏ¹Ì´Â ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¿¬±¸°³¹ß ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÁÖ¿ä ¼öÀÔ¿øÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé µ¶°¨¹é½Å ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¸¶ÀÌÅ©·Î´Ïµé µ¶°¨ ¹é½Å ¼¼°è ½ÃÀåÀº Á¦Ç° À¯Çü, ¹é½Å À¯Çü, ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

Á¦Ç° À¯Çü¿¡ µû¶ó °íü ¸¶ÀÌÅ©·Î´Ïµé°ú Áß°ø ¸¶ÀÌÅ©·Î´Ïµé µÎ °¡Áö·Î ³ª´¹´Ï´Ù. Áß°øÇü ¸¶ÀÌÅ©·Î´Ïµé ºÎ¹®ÀÌ ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. Áß°øÇü ¸¶ÀÌÅ©·Î´Ïµé ºÎ¹®Àº ¹é½Å Àü´ÞÀÇ ³ôÀº ½Å·Ú¼ºÀÌ Áß°øÇü ¸¶ÀÌÅ©·Î´Ïµé¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¹é½Å À¯Çü¿¡ µû¶ó 4°¡ µ¶°¨ ¹é½Å°ú 3°¡ µ¶°¨ ¹é½ÅÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´µ¸ç, 4°¡ µ¶°¨ ¹é½Å ºÐ¾ß´Â 4°¡ µ¶°¨ ¹é½Å ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, 4°¡ µ¶°¨ ¹é½ÅÀº AÇü°ú BÇü µ¶°¨ ±ÕÁÖ¿¡ ´ëÇÑ ¿¹¹æ È¿°ú¸¦ Á¦°øÇϰí, 4°¡ µ¶°¨ ¹é½ÅÀº AÇü°ú BÇü µ¶°¨ ±ÕÁÖ¿¡ ´ëÇÑ ¿¹¹æ È¿°ú¸¦ Á¦°øÇÑ´Ù, ÀÌ ºÐ¾ß ¼ö¿ä¸¦ Áõ°¡½Ãŵ´Ï´Ù.

ÀÌ ½ÃÀåÀº ¿ëµµº°·Î ¿¬±¸ ¹× ÀÓ»ó½ÃÇè, ¾à¹°Àü´Þ, ±âŸ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ¾à¹°Àü´Þ ºÐ¾ß´Â ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¶ÀÌÅ©·Î´ÏµéÀº ¹é½Å Àü´Þ¿¡ ÀÖÀ¸¸ç, º¸´Ù È¿À²ÀûÀÌ°í ½Å·ÚÇÒ ¼ö ÀÖÀ¸¸ç »ç¿ëÀÚ Ä£È­ÀûÀ̱⠶§¹®¿¡ ¾à¹°Àü´Þ ºÐ¾ß¿¡¼­ ¸¶ÀÌÅ©·Î´Ïµé¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé µ¶°¨¹é½Å ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ºÏ¹Ì¿¡¼­´Â Ȱ¹ßÇÑ R&D ÀÚ±Ý, »ý¸í°øÇÐ ±â¾÷ÀÇ Á¸Àç, ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀ¸·Î ¹Ì±¹ÀÌ ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ³ôÀº ÀÎÁöµµ, ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, Çõ½ÅÀûÀÎ ¹é½Å ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä. ¶ÇÇÑ ¸¶ÀÌÅ©·Î´Ïµé ±â¼ú ÀÓ»ó½ÃÇè ¹× FDA ½ÂÀο¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹ÀÌ Çõ½ÅÀûÀÎ ¹é½Å ±â¼ú äÅÃÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Áß±¹, ÀϺ», Àεµ°¡ Å« ¼ºÀå ±âȸ¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

¸¶ÀÌÅ©·Î´ÏµéÇü µ¶°¨ ¹é½Å ½ÃÀå - °æÀï»óȲ:

¸¶ÀÌÅ©·Î´Ïµé µ¶°¨ ¹é½Å ½ÃÀåÀÇ ¼º°ÝÀº ¿Ï¸¸Çϸç, Á¦¾à »ê¾÷°ú ÇÔ²² ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â °ÍÀº ÅëÁõ ¾ø´Â ¹é½Å Àü´Þ ±â¼úÀÇ Çõ½ÅÀÔ´Ï´Ù. ¸¶ÀÌÅ©·Î´Ïµé ±â¼úÀº ƯÈ÷ ¿Üµý Áö¿ªÀ̳ª ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ ¹é½Å¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀÏ ¼ö ÀÖ´Â ÀáÀç·ÂÀ¸·Î ÀÎÇØ ÀÎÁöµµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. °¢ ±â¾÷Àº ´õ ³ôÀº È¿´É°ú ´õ ³·Àº ºñ¿ëÀ» ´Þ¼ºÇϱâ À§ÇØ Ã·´Ü ¼ÒÀç¿Í ¼³°è¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀϺΠ±â¾÷Àº WHO ¹× °ÔÀÌÃ÷ Àç´Ü°ú Çù·ÂÇÏ¿© Àú¼Òµæ ±¹°¡¿¡ ¹èÆ÷Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀϺΠÁÖ¿ä ±â¾÷Àº Áõ°¡ÇÏ´Â ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡ Á¦Á¶ ½Ã¼³À» °Ç¼³Çϰí ÀÖ½À´Ï´Ù.

2023³â Vaxxas´Â BARDA(Biomedical Advanced Research and Development Authority)¿Í °°Àº ±â°üÀ¸·ÎºÎÅÍ µ¶°¨ ¹é½Å ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡¸¦ °³¹ßÇϱâ À§ÇÑ º¸Á¶±ÝÀ» ¹Þ¾Ò½À´Ï´Ù.

2022³â 11¿ù, Micron Biomedical, Inc.´Â »ó¾÷ »ý»êÀ» °­È­Çϱâ À§ÇØ ÅõÀÚ¸¦ ÅëÇØ 1,400¸¸ ´Þ·¯ÀÇ ÅõÀÚ¸¦ ¹Þ¾Ò½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½ÅÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å »ê¾÷ ¿¬±¸

Á¦5Àå ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå ±¸µµ

Á¦7Àå ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå - Á¦Ç° À¯Çüº°

Á¦8Àå ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå - ¹é½Å À¯Çüº°

Á¦9Àå ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå - ¿ëµµº°

Á¦10Àå ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¸¶ÀÌÅ©·Î´ÏµéÇü ÀÎÇ÷翣ÀÚ ¹é½Å ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Microneedle Flu Vaccine Market Application was valued at USD 1,630.43 Million in 2023, expanding at a CAGR of 6.30% from 2024 to 2032.

The microneedle flu vaccine is an innovative approach to delivering influenza vaccines using microneedles, which are tiny needles typically smaller than a millimeter embedded in a small patch or device. This technology is designed to make vaccination easier, less painful, and potentially more accessible compared to traditional syringe-based methods.

Microneedle Flu Vaccine Market- Market Dynamics

Increasing demand for enhanced vaccine delivery & needle-free administration is expected to propel market demand

Microneedle flu vaccination provides enhanced immune response through intradermal delivery. Increased interest in more effective and patient-friendly vaccine technologies. Needle-free administration reduces fear and anxiety associated with traditional needle-based vaccines, increasing patient compliance, thereby boosting market growth. Also, increasing recognition of influenza's public health impact drives vaccine adoption. The COVID-19 pandemic highlighted the need for scalable, accessible, and efficient vaccine solutions, increasing interest in microneedle technology. Campaigns emphasizing universal immunization boost demand for innovative delivery systems.

Older adult population, particularly vulnerable to influenza, requires safer and more comfortable vaccination methods. Further, the growing preference for home healthcare solutions aligns with the self-administered nature of microneedle patches. It eliminates sharps waste, reducing environmental impact and the need for specialized disposal systems. Lowers the risk of needle-stick injuries for healthcare workers. Furthermore, microneedle systems are being used for certain applications such as drug delivery, and widespread commercial use is contributing to market growth.

Microneedle Flu Vaccine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.30% over the forecast period (2024-2032)

Based on Product Type segmentation, the hollow microneedle segment was predicted to show maximum market share in 2023, owing to their effectiveness in vaccines.

Based on Vaccine Type segmentation, the quadrivalent flu vaccine segment was the leading Vaccine Type segment in 2023, due to wider applications in virus strains.

Based on application segmentation, the drug delivery segment was the leading application segment in 2023, mainly due to its greater accessibility and regulatory support.

On the basis of region, North America was the leading revenue generator in 2023, due to the increasing R&D investment in drug delivery.

Microneedle Flu Vaccine Market- Segmentation Analysis:

Global Microneedle Flu Vaccine Market is segmented on the basis of Product Type, Vaccine Type, Application, and Region.

The market is divided into two categories based on the Product Type: solid microneedle and hollow microneedle. The hollow microneedle segment dominates the market. The greater reliability in delivering the vaccine is boosting demand for hollow microneedle.

The market is divided into two categories based on Vaccine Type: quadrivalent flu vaccine and trivalent flu vaccine. The quadrivalent flu vaccine segment dominates the market. The quadrivalent flu vaccine provides protection against influenza A & B strains, increasing segment demand.

The market is divided into three categories based on Application: research & clinical trials, drug delivery, and others. The drug delivery segment is anticipated to grow at the fastest rate over the forecast period. The growing demand for microneedles in drug delivery as they are more efficient & reliable in vaccine deliverables & user-friendly is expected to fuel segment growth.

Microneedle Flu Vaccine Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. In North America, the U.S. dominates this market due to robust R&D funding, presence of biotech firms, and regulatory support. High awareness, advanced healthcare infrastructure, and demand for innovative vaccine solutions. Also, there is increasing investment in clinical trials and FDA approvals for microneedle technology. In Europe, Germany, France, and the UK lead in adopting innovative vaccine technologies. In Asia Pacific region, China, Japan, and India show significant growth potential opportunities.

Microneedle Flu Vaccine Market- Competitive Landscape:

The Microneedle Flu Vaccine market is moderately in nature and is rapidly evolving with pharma industry. The market is driven by innovations in painless vaccine delivery technologies. Microneedle technology is being increasingly recognized for its potential to enhance vaccine accessibility, particularly in remote or resource-limited settings. Companies are heavily investing in advanced materials and designs for higher efficacy and lower costs. Several companies have partnered with WHO or Gates Foundation for distribution in low-income countries. Some of the top players are building manufacturing units in Asia-Pacific to meet growing demand.

In 2023, Vaxxas have received grants from agencies like BARDA (Biomedical Advanced Research and Development Authority) to advance & develop flu vaccine microneedle patches.

In November 2022, Micron Biomedical, Inc. received USD 14 million through their investment to bolster its commercial manufacturing.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MICRONEEDLE FLU VACCINE MARKET KEY PLAYERS

GLOBAL MICRONEEDLE FLU VACCINE MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL MICRONEEDLE FLU VACCINE MARKET, BY VACCINE TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL MICRONEEDLE FLU VACCINE MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

GLOBAL MICRONEEDLE FLU VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Microneedle Flu Vaccine Market Overview

2. Executive Summary

3. Microneedle Flu Vaccine Key Market Trends

4. Microneedle Flu Vaccine Industry Study

5. Microneedle Flu Vaccine Market: COVID-19 Impact Analysis

6. Microneedle Flu Vaccine Market Landscape

7. Microneedle Flu Vaccine Market - By Product Type

8. Microneedle Flu Vaccine Market - By Vaccine Type

9. Microneedle Flu Vaccine Market - By Application

10. Microneedle Flu Vaccine Market- By Geography

11. Key Vendor Analysis- Microneedle Flu Vaccine Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â